相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis
Anthony I. Sebba et al.
BONE (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?
Ernest Beng Kee Kwek et al.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED (2008)
Severely suppressed bone turnover and atypical skeletal fragility
Maja Visekruna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Low-energy femoral shaft fractures associated with alendronate use
Andrew S. Neviaser et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2008)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Trabecular bone gradient in rat long bone metaphyses: Mathematical modeling and application to morphometric measurements and correction of implant positioning
Yankel Gabet et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
Steven T. Harris et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in calcium Homeostasis
J. Wesley Pike et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Consequences of poor compliance with bisphosphonates
Becky A. Briesacher et al.
BONE (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates
S. R. Earnshaw et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills
Thomas W. Weiss et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Non-compliance:: the Achilles' heel of anti-fracture efficacy
E. Seeman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Alendronate and atrial fibrillation
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study
A. Cooper et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Drug insight: bisphosphonates for postmenopausal osteoporosis
RD Chapurlat et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis
FJA Penning-van Beest et al.
CLINICAL THERAPEUTICS (2006)
Initial characterization of PTH-related protein gene-driven lacZ expression in the mouse
XS Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The population burden of fractures originates in women with osteopenia, not osteoporosis
J. A. Pasco et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study
Pierre D. Delmas et al.
ARTHRITIS AND RHEUMATISM (2006)
Compliance with osteoporosis medications
DH Solomon et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Daily and cyclic parathyroid hormone in women receiving alendronate
F Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
RR Recker et al.
MAYO CLINIC PROCEEDINGS (2005)
Underdiagnosis of vertebral fractures is a worldwide problem: The IMPACT study
PD Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Efficacy and safety of ibandronate given by intravenous injection once every 3 months
S Adami et al.
BONE (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Bone mineral density thresholds for pharmacological intervention to prevent fractures
ES Siris et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Low frequency of treatment of osteoporosis among postmenopausal women following a fracture
SE Andrade et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women - Results from the National Osteoporosis Risk Assessment
ES Siris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
